We recently extended this finding and found that EGCG inhibits the activation of EGFR, HER2, and HER3, and their multiple downstream signaling pathways in human HNSCC, breast cancer, and colon cancer cell lines [10, 11, 13, 15]. Here, ERBB2 is linked to malignant colon neoplasm.